Mo Neuro222 retweeted
FDA approves asundexian + antiplatelets after non-cardioembolic ischaemic stroke/high-risk TIA.
OCEANIC-STROKE: ischaemic stroke 6.2% vs 8.4%.
Bleeding precautions remain. Not approved for AF stroke prevention.
The conundrum of being can be vastly more difficult to wrestle with if there is no sanctum on the inside to revert to in difficult moments.
On this blessed Friday I pray for a better inner sanctum & for fleeting moments of peace to rest in ones soul.
35
721
Mo Neuro222 retweeted
"I sit in my room, surrounded by silence, but inside me there is a storm that never stops."
— Franz Kafka, Diaries, 1913
Mo Neuro222 retweeted
Obesity in children with #IBD is the new elephant in the room
This timely review in @JPGNonline explores the growing challenge of obesity in children with IBD:
✅ Beyond undernutrition, impaired growth, and delayed puberty, it's time to also consider obesity in children with IBD
❗Excess adipose tissue may adversely affect disease presentation, outcomes, and treatment response
✅ Body mass index is not enough as a measure of body composition
✅ Children with IBD exhibit poorer diet quality with:
🔸 high ratio of animal-to-plant protein
🔸 high ratio of omega-6 to omega-3 fatty acid intake
🔸 ⬇️ fiber intake
🔸 ⬇️ iron
🔸⬇️ zinc
🔸 ⬇️ vitamin D
📚 Read the full review here: onlinelibrary.wiley.com/doi/…
Stauffer syndrome,a paraneoplastic hepatopathy phenomenon
•classically desc w/ RCC (but now reported w/ several other malignancies)
•2 variants: classical / Icteric
•Impt in DDx of unexplained cholestasis
•⬆️ ALP is the m/c abnormality (in >90%, some case reports in image)
2
189
•Liver abnormalities & cholestasis are REVERSIBLE w/Tx/resolution of the 1ry tumor
•There will be no liver/biliary lesion or metastasis to explain the liver function profile or any anatomic obstruction of bile flow
•Almost universal A/w IL-6
In 1 study antiIL6AB reversed it
1
109
Bec of the severity & progression of the cholestasis they did a percut. Liver biopsy: hepatic architecture preserved, non specific cholestatic changes, no malignancy/bile duct injury/CLD!
1
43
Mo Neuro222 retweeted
Encouraging news for pancreatic cancer!
At ENA 2026, daraxonrasib (an oral RAS inhibitor) + gemcitabine/nab-paclitaxel showed promising first-line results in metastatic pancreatic cancer (61 patients):
• Tumor shrinkage in 61% of patients (ORR), including 8% complete responses
• Median PFS of 12.8 months
• 77% alive at one year
For context, historical results with gemcitabine/nab-paclitaxel (MPACT) showed a 23% response rate and 5.5-month median PFS.
Very encouraging, but this was a small, nonrandomized study. The phase 3 RASolute-303 trial will help determine whether adding daraxonrasib truly improves outcomes.
An unlimited archive on matters concerning the therapeutic use of the knife & other related aspects that may or may not appear strange , random or inconsequential.
I'll embedd what concerns the neurologist on general surgery as well, only that would be of great interest indeed
6
271
Mo Neuro222 retweeted
🩸 Portal vein thrombosis affects 1 in 10 hospitalized patients with cirrhosis worldwide.
🌍 In the CLEARED cohort (n=7,721), PVT independently predicted 30-day mortality (OR 1.5) and was linked to more complications.
doi.org/10.1097/LVT.00000000…
#LiverTwitter
Mo Neuro222 retweeted
📑 ApiHep RCT: Adding apixaban to standard medical treatment in Child-Pugh B7-C10 cirrhosis
⬇️ 1-yr hepatic decompensation (33.1% vs 54.3%)
🩸 without increased bleeding risk‼️
ovid.com/10.1097/HC9.0000000…
@ebtapper @HepCommJournal @aiims_newdelhi
Mo Neuro222 retweeted
We have just updated our distal hereditary motor neuropathy genetics checklist with this paper neurochecklists.com/explore/…
Mo Neuro222 retweeted
Atypical Cogan syndrome associated with marginal zone lymphoma presenting with unusual ocular findings and central nervous system vasculitis: a case report
link.springer.com/article/10…




























